{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:23:42Z","timestamp":1770996222955,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,7,23]],"date-time":"2016-07-23T00:00:00Z","timestamp":1469232000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81503157"],"award-info":[{"award-number":["81503157"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81373264"],"award-info":[{"award-number":["81373264"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Organization Department of Beijing Municipal Committee","award":["2014000021469G258"],"award-info":[{"award-number":["2014000021469G258"]}]},{"DOI":"10.13039\/501100002799","name":"Capital Medical University","doi-asserted-by":"publisher","award":["16JL72"],"award-info":[{"award-number":["16JL72"]}],"id":[{"id":"10.13039\/501100002799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s00228-016-2094-1","type":"journal-article","created":{"date-parts":[[2016,7,23]],"date-time":"2016-07-23T18:05:24Z","timestamp":1469297124000},"page":"1195-1204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis"],"prefix":"10.1007","volume":"72","author":[{"given":"Zhigang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongrong","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiqi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,23]]},"reference":[{"key":"2094_CR1","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1161\/Strokeaha.107.502807","volume":"39","author":"D Zhao","year":"2008","unstructured":"Zhao D, Liu J, Wang W, Zeng ZC, Cheng J, Liu J, Sun JY, Wu ZS (2008) Epidemiological transition of stroke in China\u2014twenty-one-year observational study from the Sino-MONICA-Beijing project. Stroke 39:1668\u20131674. doi: 10.1161\/Strokeaha.107.502807","journal-title":"Stroke"},{"key":"2094_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.5853\/jos.2013.15.2.109","volume":"15","author":"H Sun","year":"2013","unstructured":"Sun H, Zou X, Liu L (2013) Epidemiological factors of stroke: a survey of the current status in China. J Stroke 15:109\u2013114. doi: 10.5853\/jos.2013.15.2.109","journal-title":"J Stroke"},{"key":"2094_CR3","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/Nejmoa0708028","volume":"358","author":"HS Gurm","year":"2008","unstructured":"Gurm HS, Yadav JS, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Ansel G, Strickman NE, Wang H, Cohen SA, Massaro JM, Cutlip DE, Investigators S (2008) Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med 358:1572\u20131579. doi: 10.1056\/Nejmoa0708028","journal-title":"N Engl J Med"},{"key":"2094_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/Nejmoa0912321","volume":"363","author":"TG Brott","year":"2010","unstructured":"Brott TG, Hobson RW, Howard G, Roubin GS, Clark WM, Brooks W, Mackey A, Hill MD, Leimgruber PP, Sheffet AJ, Howard VJ, Moore WS, Voeks JH, Hopkins LN, Cutlip DE, Cohen DJ, Popma JJ, Ferguson RD, Cohen SN, Blackshear JL, Silver FL, Mohr JP, Lal BK, Meschia JF, Investigators C (2010) Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 363:11\u201323. doi: 10.1056\/Nejmoa0912321","journal-title":"N Engl J Med"},{"key":"2094_CR5","first-page":"634","volume":"22","author":"DL Bhatt","year":"2001","unstructured":"Bhatt DL, Kapadia SR, Chew DP, Mukherjee D, Ziada KM, Topol EJ, Yadav JS (2001) Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. Eur Heart J 22:634\u2013634","journal-title":"Eur Heart J"},{"key":"2094_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/s0140-6736(13)62038-3","volume":"383","author":"CP Derdeyn","year":"2014","unstructured":"Derdeyn CP, Chimowitz MI, Lynn MJ, Fiorella D, Turan TN, Janis LS, Montgomery J, Nizam A, Lane BF, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL, Lynch JR, Zaidat OO, Rumboldt Z, Cloft HJ (2014) Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial. Lancet 383:333\u2013341. doi: 10.1016\/s0140-6736(13)62038-3","journal-title":"Lancet"},{"key":"2094_CR7","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.02.013","volume":"25","author":"X Yi","year":"2016","unstructured":"Yi X, Lin J, Zhou Q, Wu L, Cheng W, Wang C (2016) Clopidogrel resistance increases rate of recurrent stroke and other vascular events in Chinese population. J Stroke Cerebrovasc Dis 25:1222\u20131228. doi: 10.1016\/j.jstrokecerebrovasdis.2016.02.013","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2094_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ncl.2014.12.007","volume":"33","author":"S John","year":"2015","unstructured":"John S, Katzan I (2015) Recurrent stroke while on antiplatelet therapy. Neurol Clin 33:475\u2013489. doi: 10.1016\/j.ncl.2014.12.007","journal-title":"Neurol Clin"},{"key":"2094_CR9","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00228-014-1714-x","volume":"70","author":"X Hou","year":"2014","unstructured":"Hou X, Shi J, Sun H (2014) Gene polymorphism of cytochrome P450 2C19*2 and clopidogrel resistance reflected by platelet function assays: a meta-analysis. Eur J Clin Pharmacol 70:1041\u20131047. doi: 10.1007\/s00228-014-1714-x","journal-title":"Eur J Clin Pharmacol"},{"key":"2094_CR10","doi-asserted-by":"publisher","first-page":"e0148891","DOI":"10.1371\/journal.pone.0148891","volume":"11","author":"XQ Li","year":"2016","unstructured":"Li XQ, Ma N, Li XG, Wang B, Sun SS, Gao F, Mo DP, Song LG, Sun X, Liu L, Zhao XQ, Wang YL, Wang YJ, Zhao ZG, Miao ZR (2016) Association of PON1, P2Y12 and COX1 with recurrent ischemic events in patients with extracranial or intracranial stenting. PLoS One 11:e0148891. doi: 10.1371\/journal.pone.0148891","journal-title":"PLoS One"},{"key":"2094_CR11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clpt.2006.07.007","volume":"80","author":"D Taubert","year":"2006","unstructured":"Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schomig A, Schomig E (2006) Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 80:486\u2013501. doi: 10.1016\/j.clpt.2006.07.007","journal-title":"Clin Pharmacol Ther"},{"key":"2094_CR12","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJMoa0808227","volume":"360","author":"T Simon","year":"2009","unstructured":"Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L, French Registry of Acute STE, Non STEMII (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363\u2013375. doi: 10.1056\/NEJMoa0808227","journal-title":"N Engl J Med"},{"key":"2094_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/dmd.109.029132","volume":"38","author":"M Kazui","year":"2010","unstructured":"Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A (2010) Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38:92\u201399. doi: 10.1124\/dmd.109.029132","journal-title":"Drug Metab Dispos"},{"key":"2094_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nm.2281","volume":"17","author":"HJ Bouman","year":"2011","unstructured":"Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM, Hirschhauser C, Waldmann C, Schmalz HG, ten Berg JM, Taubert D (2011) Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 17:110\u2013116. doi: 10.1038\/nm.2281","journal-title":"Nat Med"},{"key":"2094_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1124\/jpet.112.201640","volume":"344","author":"HJ Zhu","year":"2013","unstructured":"Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS (2013) Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther 344:665\u2013672. doi: 10.1124\/jpet.112.201640","journal-title":"J Pharmacol Exp Ther"},{"key":"2094_CR16","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/cpt.101","volume":"97","author":"EK Tarkiainen","year":"2015","unstructured":"Tarkiainen EK, Holmberg MT, Tornio A, Neuvonen M, Neuvonen PJ, Backman JT, Niemi M (2015) Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin Pharmacol Ther 97:650\u2013658. doi: 10.1002\/cpt.101","journal-title":"Clin Pharmacol Ther"},{"key":"2094_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/FPC.0b013e32835aa8a2","volume":"23","author":"JP Lewis","year":"2013","unstructured":"Lewis JP, Horenstein RB, Ryan K, O\u2019Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Gurbel PA, Shuldiner AR (2013) The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics 23:1\u20138. doi: 10.1097\/FPC.0b013e32835aa8a2","journal-title":"Pharmacogenet Genomics"},{"key":"2094_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1021\/tx2004085","volume":"25","author":"PM Dansette","year":"2012","unstructured":"Dansette PM, Rosi J, Bertho G, Mansuy D (2012) Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer. Chem Res Toxicol 25:348\u2013356. doi: 10.1021\/tx2004085","journal-title":"Chem Res Toxicol"},{"key":"2094_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jjcc.2015.03.010","volume":"67","author":"N Tabata","year":"2016","unstructured":"Tabata N, Hokimoto S, Akasaka T, Arima Y, Sakamoto K, Yamamoto E, Tsujita K, Izumiya Y, Yamamuro M, Kojima S, Kaikita K, Kumagae N, Morita K, Oniki K, Nakagawa K, Matsui K, Ogawa H (2016) Patients with both CYP2C19 loss-of-function allele and peripheral endothelial dysfunction are significantly correlated with adverse cardiovascular events following coronary stent implantation. J Cardiol 67:104\u2013109. doi: 10.1016\/j.jjcc.2015.03.010","journal-title":"J Cardiol"},{"key":"2094_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","volume":"373","author":"JP Collet","year":"2009","unstructured":"Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373:309\u2013317. doi: 10.1016\/S0140-6736(08)61845-0","journal-title":"Lancet"},{"key":"2094_CR21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jama.2009.1232","volume":"302","author":"AR Shuldiner","year":"2009","unstructured":"Shuldiner AR, O\u2019Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA (2009) Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302:849\u2013857. doi: 10.1001\/jama.2009.1232","journal-title":"JAMA"},{"key":"2094_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pharmthera.2013.08.005","volume":"141","author":"CN Floyd","year":"2014","unstructured":"Floyd CN, Ferro A (2014) Mechanisms of aspirin resistance. Pharmacol Ther 141:69\u201378. doi: 10.1016\/j.pharmthera.2013.08.005","journal-title":"Pharmacol Ther"},{"key":"2094_CR23","doi-asserted-by":"publisher","first-page":"370","DOI":"10.5152\/akd.2013.107","volume":"13","author":"O Abaci","year":"2013","unstructured":"Abaci O, Kilickesmez KO (2013) Aspirin resistance: where are we now? Anadolu Kardiyol Derg 13:370\u2013373. doi: 10.5152\/akd.2013.107","journal-title":"Anadolu Kardiyol Derg"},{"key":"2094_CR24","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.2174\/092986710794182962","volume":"17","author":"M Rafferty","year":"2010","unstructured":"Rafferty M, Walters MR, Dawson J (2010) Anti-platelet therapy and aspirin resistance\u2014clinically and chemically relevant? Curr Med Chem 17:4578\u20134586","journal-title":"Curr Med Chem"},{"key":"2094_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.pharmthera.2011.01.011","volume":"130","author":"R Fitzgerald","year":"2011","unstructured":"Fitzgerald R, Pirmohamed M (2011) Aspirin resistance: effect of clinical, biochemical and genetic factors. Pharmacol Ther 130:213\u2013225. doi: 10.1016\/j.pharmthera.2011.01.011","journal-title":"Pharmacol Ther"},{"key":"2094_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1365-2125.2008.03183.x","volume":"66","author":"T Goodman","year":"2008","unstructured":"Goodman T, Ferro A, Sharma P (2008) Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol 66:222\u2013232. doi: 10.1111\/j.1365-2125.2008.03183.x","journal-title":"Br J Clin Pharmacol"},{"key":"2094_CR27","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1160\/TH13-10-0891","volume":"112","author":"PA Gurbel","year":"2014","unstructured":"Gurbel PA, Bergmeijer TO, Tantry US, ten Berg JM, Angiolillo DJ, James S, Lindahl TL, Svensson P, Jakubowski JA, Brown PB, Duvvuru S, Sundseth S, Walker JR, Small D, Moser BA, Winters KJ, Erlinge D (2014) The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thromb Haemost 112:589\u2013597. doi: 10.1160\/TH13-10-0891","journal-title":"Thromb Haemost"},{"key":"2094_CR28","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1160\/TH12-05-0336","volume":"109","author":"JF Carlquist","year":"2013","unstructured":"Carlquist JF, Knight S, Horne BD, Huntinghouse JA, Rollo JS, Muhlestein JB, May H, Anderson JL (2013) Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thromb Haemost 109:744\u2013754. doi: 10.1160\/TH12-05-0336","journal-title":"Thromb Haemost"},{"key":"2094_CR29","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCGENETICS.111.964627","volume":"6","author":"JP Lewis","year":"2013","unstructured":"Lewis JP, Ryan K, O\u2019Connell JR, Horenstein RB, Damcott CM, Gibson Q, Pollin TI, Mitchell BD, Beitelshees AL, Pakzy R, Tanner K, Parsa A, Tantry US, Bliden KP, Post WS, Faraday N, Herzog W, Gong Y, Pepine CJ, Johnson JA, Gurbel PA, Shuldiner AR (2013) Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet 6:184\u2013192. doi: 10.1161\/CIRCGENETICS.111.964627","journal-title":"Circ Cardiovasc Genet"},{"key":"2094_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijcard.2012.08.017","volume":"165","author":"H Wu","year":"2013","unstructured":"Wu H, Qian J, Xu J, Sun A, Sun W, Wang Q, Ge J (2013) Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients. Int J Cardiol 165:204\u2013206. doi: 10.1016\/j.ijcard.2012.08.017","journal-title":"Int J Cardiol"},{"key":"2094_CR31","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.thromres.2015.08.025","volume":"136","author":"B Calderon-Cruz","year":"2015","unstructured":"Calderon-Cruz B, Rodriguez-Galvan K, Manzo-Francisco LA, Vargas-Alarcon G, Fragoso JM, Pena-Duque MA, Reyes-Gomez CA, Martinez-Rios MA, dela Pena-Diaz A (2015) C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention. Thromb Res 136:894\u2013898. doi: 10.1016\/j.thromres.2015.08.025","journal-title":"Thromb Res"},{"key":"2094_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/clpt.2011.221","volume":"91","author":"JT Delaney","year":"2012","unstructured":"Delaney JT, Ramirez AH, Bowton E, Pulley JM, Basford MA, Schildcrout JS, Shi Y, Zink R, Oetjens M, Xu H, Cleator JH, Jahangir E, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC (2012) Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther 91:257\u2013263. doi: 10.1038\/clpt.2011.221","journal-title":"Clin Pharmacol Ther"},{"key":"2094_CR33","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/clpt.2013.105","volume":"94","author":"SA Scott","year":"2013","unstructured":"Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR, Clinical Pharmacogenetics Implementation C (2013) Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94:317\u2013323. doi: 10.1038\/clpt.2013.105","journal-title":"Clin Pharmacol Ther"},{"key":"2094_CR34","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00228-015-1882-3","volume":"71","author":"N Simon","year":"2015","unstructured":"Simon N, Finzi J, Cayla G, Montalescot G, Collet JP, Hulot JS (2015) Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol 71:1059\u20131066. doi: 10.1007\/s00228-015-1882-3","journal-title":"Eur J Clin Pharmacol"},{"key":"2094_CR35","doi-asserted-by":"publisher","first-page":"e001652","DOI":"10.1161\/JAHA.114.001652","volume":"4","author":"CW McDonough","year":"2015","unstructured":"McDonough CW, McClure LA, Mitchell BD, Gong Y, Horenstein RB, Lewis JP, Field TS, Talbert RL, Benavente OR, Johnson JA, Shuldiner AR (2015) CYP2C19 metabolizer status and clopidogrel efficacy in the secondary prevention of small subcortical strokes (SPS3) study. J Am Heart Assoc 4:e001652. doi: 10.1161\/JAHA.114.001652","journal-title":"J Am Heart Assoc"},{"key":"2094_CR36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1161\/CIRCGENETICS.114.000669","volume":"7","author":"MJ Sorich","year":"2014","unstructured":"Sorich MJ, Rowland A, McKinnon RA, Wiese MD (2014) CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet 7:895\u2013902. doi: 10.1161\/CIRCGENETICS.114.000669","journal-title":"Circ Cardiovasc Genet"},{"key":"2094_CR37","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1161\/ATVBAHA.110.217182","volume":"31","author":"KW Park","year":"2011","unstructured":"Park KW, Park JJ, Jeon KH, Kang SH, IY O, Yang HM, Cho HJ, Lee HY, Kang HJ, Koo BK, BH O, Park YB, Kim HS (2011) Enhanced clopidogrel responsiveness in smokers: smokers\u2019 paradox is dependent on cytochrome P450 CYP1A2 status. Arterioscler Thromb Vasc Biol 31:665\u2013671. doi: 10.1161\/ATVBAHA.110.217182","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2094_CR38","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.atherosclerosis.2006.11.009","volume":"196","author":"B Giusti","year":"2008","unstructured":"Giusti B, Gori AM, Marcucci R, Sestini I, Saracini C, Paniccia R, Poli S, Giglioli C, Valente S, Prisco D, Gensini GF, Abbate R (2008) Role of glycoprotein Ia gene polymorphisms in determining platelet function in myocardial infarction patients undergoing percutaneous coronary intervention on dual antiplatelet treatment. Atherosclerosis 196:341\u2013348. doi: 10.1016\/j.atherosclerosis.2006.11.009","journal-title":"Atherosclerosis"},{"key":"2094_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11010-012-1419-3","volume":"370","author":"YA Shuvalova","year":"2012","unstructured":"Shuvalova YA, Kaminnyi AI, Meshkov AN, Shirokov RO, Samko AN (2012) Association between polymorphisms of eNOS and GPx-1 genes, activity of free-radical processes and in-stent restenosis. Mol Cell Biochem 370:241\u2013249. doi: 10.1007\/s11010-012-1419-3","journal-title":"Mol Cell Biochem"},{"key":"2094_CR40","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMoa060900","volume":"354","author":"E Lonn","year":"2006","unstructured":"Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr, Heart Outcomes Prevention Evaluation I (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354:1567\u20131577. doi: 10.1056\/NEJMoa060900","journal-title":"N Engl J Med"},{"key":"2094_CR41","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","volume":"46","author":"SM Morais De","year":"1994","unstructured":"De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46:594\u2013598","journal-title":"Mol Pharmacol"},{"key":"2094_CR42","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","volume":"56","author":"JS Hulot","year":"2010","unstructured":"Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, Cayla G, Beygui F, Montalescot G (2010) Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration a systematic meta-analysis. J Am Coll Cardiol 56:134\u2013143. doi: 10.1016\/j.jacc.2009.12.071","journal-title":"J Am Coll Cardiol"},{"key":"2094_CR43","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2010.1543","volume":"304","author":"JL Mega","year":"2010","unstructured":"Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot JS, Kastrati A, Montalescot G, Neumann FJ, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS (2010) Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI a meta-analysis. JAMA 304:1821\u20131830. doi: 10.1001\/jama.2010.1543","journal-title":"JAMA"},{"key":"2094_CR44","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.amjcard.2012.04.020","volume":"110","author":"JS Jang","year":"2012","unstructured":"Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Seol SH, Kim DI, Kim BH, Park YH, Je HG, Jeong YH, Lee SW (2012) Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol 110:502\u2013508. doi: 10.1016\/j.amjcard.2012.04.020","journal-title":"Am J Cardiol"},{"key":"2094_CR45","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.ajhg.2008.04.015","volume":"82","author":"HJ Zhu","year":"2008","unstructured":"Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, Langaee TY, Markowitz JS (2008) Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 82:1241\u20131248. doi: 10.1016\/j.ajhg.2008.04.015","journal-title":"Am J Hum Genet"},{"key":"2094_CR46","doi-asserted-by":"publisher","first-page":"e46366","DOI":"10.1371\/journal.pone.0046366","volume":"7","author":"J Su","year":"2012","unstructured":"Su J, Xu J, Li X, Zhang H, Hu J, Fang R, Chen X (2012) ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One 7:e46366. doi: 10.1371\/journal.pone.0046366","journal-title":"PLoS One"},{"key":"2094_CR47","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","volume":"39","author":"SV Ambudkar","year":"1999","unstructured":"Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361\u2013398. doi: 10.1146\/annurev.pharmtox.39.1.361","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2094_CR48","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","volume":"108","author":"P Fontana","year":"2003","unstructured":"Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, Gaussem P (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989\u2013995. doi: 10.1161\/01.CIR.0000085073.69189.88","journal-title":"Circulation"},{"key":"2094_CR49","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1097\/FPC.0b013e3282f1b2be","volume":"17","author":"B Giusti","year":"2007","unstructured":"Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF (2007) Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G\/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 17:1057\u20131064. doi: 10.1097\/FPC.0b013e3282f1b2be","journal-title":"Pharmacogenet Genomics"},{"key":"2094_CR50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1471-2350-8-59","volume":"8","author":"U Cavallari","year":"2007","unstructured":"Cavallari U, Trabetti E, Malerba G, Biscuola M, Girelli D, Olivieri O, Martinelli N, Angiolillo DJ, Corrocher R, Pignatti PF (2007) Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med Genet 8:59. doi: 10.1186\/1471-2350-8-59","journal-title":"BMC Med Genet"},{"key":"2094_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1136\/bmj.39405.635498.80","volume":"336","author":"G Biondi-Zoccai","year":"2008","unstructured":"Biondi-Zoccai G, Lotrionte M (2008) Aspirin resistance in cardiovascular disease. BMJ 336:166\u2013167. doi: 10.1136\/bmj.39405.635498.80","journal-title":"BMJ"},{"key":"2094_CR52","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1161\/CIRCULATIONAHA.112.117283","volume":"127","author":"T Grosser","year":"2013","unstructured":"Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA (2013) Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation 127:377\u2013385. doi: 10.1161\/CIRCULATIONAHA.112.117283","journal-title":"Circulation"},{"key":"2094_CR53","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1055\/s-2007-969036","volume":"33","author":"GH Rao","year":"2007","unstructured":"Rao GH, Michiels JJ (2007) Aspirin resistance: does it exist? Semin Thromb Hemost 33:210\u2013214. doi: 10.1055\/s-2007-969036","journal-title":"Semin Thromb Hemost"},{"key":"2094_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.26428","author":"GW Reed","year":"2016","unstructured":"Reed GW, Cannon CP, Waalen J, Teirstein PS, Tanguay JF, Berger PB, Angiolillo DJ, Price MJ (2016) Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: insights from the GRAVITAS trial. Catheter Cardiovasc Interv. doi: 10.1002\/ccd.26428","journal-title":"Catheter Cardiovasc Interv"},{"key":"2094_CR55","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.09.010","volume":"25","author":"I Nakagawa","year":"2016","unstructured":"Nakagawa I, Park HS, Yokoyama S, Wada T, Hironaka Y, Motoyama Y, Takayama K, Kichikawa K, Nakase H (2016) Influence of diabetes mellitus and cigarette smoking on variability of the clopidogrel-induced antiplatelet effect and efficacy of active management of the target P2Y12 reaction unit range in patients undergoing neurointerventional procedures. J Stroke Cerebrovasc Dis 25:163\u2013171. doi: 10.1016\/j.jstrokecerebrovasdis.2015.09.010","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2094_CR56","doi-asserted-by":"crossref","first-page":"726","DOI":"10.2105\/AJPH.86.5.726","volume":"86","author":"M Aickin","year":"1996","unstructured":"Aickin M, Gensler H (1996) Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health 86:726\u2013728","journal-title":"Am J Public Health"},{"key":"2094_CR57","doi-asserted-by":"publisher","first-page":"9440","DOI":"10.1073\/pnas.1530509100","volume":"100","author":"JD Storey","year":"2003","unstructured":"Storey JD, Tibshirani R (2003) Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 100:9440\u20139445. doi: 10.1073\/pnas.1530509100","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2094-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2094-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2094-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:08:53Z","timestamp":1749010133000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2094-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,23]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["2094"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2094-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,23]]}}}